BACKGROUND: Cytokine production at the materno-fetal interface may influence the development of atopy-predisposing immune responses. Because IL-13 possesses IL-4-like activity and may regulate the immune responses observed in atopy, it may contribute to the expression of the atopic phenotype initiated during intrauterine life. OBJECTIVE: We sought to examine IL-13 expression by fetal and neonatal cells and the placenta. METHODS: The production of IL-13 by neonatal and fetal T cells was examined by culturing the cells in the presence or absence of PHA. Production of IL-13 at term was considered in the context of the later development of atopic disease in the child. IL-13 expression in the placenta was assessed by using immunohistochemistry. RESULTS: IL-13 immunoreactivity within the placenta was restricted to 16 to 27 weeks' gestation (6/6 positive vs 0/10 at >27 weeks' gestation). In contrast, spontaneous release of IL-13 by fetal mononuclear cells was first observed from 27 weeks' gestation but was undetectable after 37 weeks' gestation. PHA-stimulated mononuclear cells showed increased IL-13 levels in 80% of samples. Term babies (>37 weeks' gestation) with a parental history of atopy with atopic symptoms by 3 years of age produced significantly lower concentrations of PHA-induced IL-13 when compared with babies with no parental history of atopy (P =.034). CONCLUSION: Thus babies at risk of atopic disease in infancy display defective IL-13 production at birth. This may represent an inherent immaturity in the development of T cell-cytokine responses in babies at genetic risk for atopy or could be a consequence of downregulation of responses by other factors. Normal pregnancy, irrespective of atopic status, is associated with the production of appreciable quantities of IL-13 initially by the placenta and subsequently by the fetus. The regulation of this production and its consequences for the mother and fetus remains to be elaborated.
BACKGROUND: Cytokine production at the materno-fetal interface may influence the development of atopy-predisposing immune responses. Because IL-13 possesses IL-4-like activity and may regulate the immune responses observed in atopy, it may contribute to the expression of the atopic phenotype initiated during intrauterine life. OBJECTIVE: We sought to examine IL-13 expression by fetal and neonatal cells and the placenta. METHODS: The production of IL-13 by neonatal and fetal T cells was examined by culturing the cells in the presence or absence of PHA. Production of IL-13 at term was considered in the context of the later development of atopic disease in the child. IL-13 expression in the placenta was assessed by using immunohistochemistry. RESULTS:IL-13 immunoreactivity within the placenta was restricted to 16 to 27 weeks' gestation (6/6 positive vs 0/10 at >27 weeks' gestation). In contrast, spontaneous release of IL-13 by fetal mononuclear cells was first observed from 27 weeks' gestation but was undetectable after 37 weeks' gestation. PHA-stimulated mononuclear cells showed increased IL-13 levels in 80% of samples. Term babies (>37 weeks' gestation) with a parental history of atopy with atopic symptoms by 3 years of age produced significantly lower concentrations of PHA-induced IL-13 when compared with babies with no parental history of atopy (P =.034). CONCLUSION: Thus babies at risk of atopic disease in infancy display defective IL-13 production at birth. This may represent an inherent immaturity in the development of T cell-cytokine responses in babies at genetic risk for atopy or could be a consequence of downregulation of responses by other factors. Normal pregnancy, irrespective of atopic status, is associated with the production of appreciable quantities of IL-13 initially by the placenta and subsequently by the fetus. The regulation of this production and its consequences for the mother and fetus remains to be elaborated.
Authors: Frank D Vladich; Susan M Brazille; Debra Stern; Michael L Peck; Raffaella Ghittoni; Donata Vercelli Journal: J Clin Invest Date: 2005-03 Impact factor: 14.808
Authors: Nancy J Andersen; Tapan Kumar Mondal; Mark T Preissler; Brian M Freed; Sabine Stockinger; Erin Bell; Charlotte Druschel; Germaine M Buck Louis; David A Lawrence Journal: J Immunol Methods Date: 2013-12-13 Impact factor: 2.303
Authors: B Schaub; K G Tantisira; F K Gibbons; H He; A A Litonjua; M W Gillman; S Weiss; D L Perkins; D R Gold; P W Finn Journal: J Clin Immunol Date: 2005-07 Impact factor: 8.317
Authors: Janet Rothers; Marilyn Halonen; Debra A Stern; I Carla Lohman; Sara Mobley; Amber Spangenberg; Dayna Anderson; Anne L Wright Journal: J Allergy Clin Immunol Date: 2011-06-16 Impact factor: 10.793
Authors: James E Gern; Cynthia M Visness; Peter J Gergen; Robert A Wood; Gordon R Bloomberg; George T O'Connor; Meyer Kattan; Hugh A Sampson; Frank R Witter; Megan T Sandel; Wayne G Shreffler; Rosalind J Wright; Samuel J Arbes; William W Busse Journal: BMC Pulm Med Date: 2009-05-08 Impact factor: 3.317